Jeffrey Evans, Ph.D. is a pharmaceutical entrepreneur, with a long
history of successful drug development. Currently Dr. Evans serves as Business
and Corporate Development consultant to NYSARC, Inc.. Prior to joining NYSARC,
Dr. Evans was CEO of CWS Packaging, Sr. Director of Integrated Drug Development
for CML/AAI, and founder/CEO of Oncoholdings. Dr. Evans is well known in the
industry as co-founder and past President of Rondaxe, a leading pharmaceutical
consultancy. At Rondaxe, Dr. Evans developed and implemented an innovative
business model focused on enabling emerging pharmaceutical companies to
achieve their technical, strategic and financial goals. In this role, Dr. Evans
helped dozens of companies realize their development and partnering goals.
Companies such as Exelixis, Metabolex, Helsinn, Array, and Endece have
benefited significantly from his guidance.
Prior to founding Rondaxe, Dr. Evans enjoyed a career at Bristol-Myers
Squibb starting as a Sr. Scientist and culminating as Director of Worldwide
Development Sourcing and Planning. Dr. Evans currently serves on the Board of
Directors of the Central New York Biotechnology Center, and the Scientific
Advisory Board of Novelix Pharmaceuticals. Dr. Evans is a past board member of
the Onondaga County Resource Recovery Agency, where he served as Treasurer.
Jeff earned his B.Sc. in Chemistry at the State University of New York at
Oswego and his Ph.D. in Organic Chemistry at Syracuse University.
We aim at building true and tailored collaboration models united by an innovation and outcome driven mindset and strongly focusing on the patients as we adhere to our mission ‘Science For A Better Life’.
Our collaborations range from strategic alliances in basic research and the development of new technologies to concrete R&D projects in our core therapeutic areas or co-development and co-commercialization agreements. In the years to come, we plan to further extend our partnering activities and invest even more in collaboration and external innovation.